AUTHORS' REPLY Studies in a variety of species [1] [2] [3] indicate that a substantial proportion of the recirculating T cell population is sequestered for significant periods during transit through the lung vascular bed, and many of these cells extravasate and move into the lung interstitium. The initial trapping of T cells in transit is due, at least in part, to local endothelial expression of inflammation associated molecules such as ICAM-1. This process is partially selective for recently activated T cells, and T lymphoblasts generated at immunoinflammatory foci distal to the lung readily enter the lung and therefore contribute to the local immunological milieu. 3 4 Moreover, the extremely large size of this peripheral lung T cell population indicates that this is a physiological process which operates continuously in normal individuals, 1-3 and it is conceivable (in our view highly likely) that it is further amplified in immunoinflammatory diseases in which high numbers of activated T cells are present in the circulation. 4 As inferred by Dr Grange, these T cells are subjected to the powerful downregulatory influence of lung macrophages during their transit through lung tissue, resulting in a variety of functional changes including loss of proliferation capacity.
1 3 5 While the precise mechanisms employed by the macrophages to modulate T cells are incompletely understood, it is clear that their overall eYciency in this regard is a reflection of their maturation/ activation status. 6 The suggestion that amplification of this process during inflammatory diseases characterised by enhanced lung macrophage recruitment/activation may result in significant eVects on the overall recirculating T cell compartment is thus worthy of more detailed investigation. Adenosine and adenosine antagonism in asthma I read with interest the excellent update on adenosine by Polosa and Holgate.
1 An important use of this challenge agent is demonstrated and adenosine antagonism as a potential treatment for asthma is revisited. However, the role of adenosine as a mediator of asthma is somewhat inconsistent with several functional observations.
Besides the fact that adenosine has dual eVects in many systems, data are availableparticularly involving the pharmacology of enprofylline (3-methyl xanthine)-which suggest that the therapeutic eYcacy of theophylline (1,3-dimethyl xanthine) in asthma may not reflect adenosine antagonism.
2 This latter aspect is significant because theophylline, at therapeutic concentrations, eVectively antagonises adenosine (at receptors and functionally in vivo).
Qualitatively diVerent from theophylline, enprofylline does not antagonise the physiological/pathophysiological actions of adenosine 2 yet enprofylline and theophylline share several pharmacological actions including cardiac stimulation, microvascular antiexudative activity, and a range of smooth muscle relaxant eVects although enprofylline is consistently about three times more potent than theophylline.
2 Equally, enprofylline is about three times more potent than theophylline in asthma as a bronchodilator, 2 as an inhibitor of histamine-induced bronchoconstriction, 2 3 as an inhibitor of late phase reactions, 2 and in maintenance therapy. 2 Indeed, it is only under artificial conditions when asthmatic subjects inhale adenosine that theophylline provides greater protection than enprofylline.
3
In contrast to its eYcacy in the treatment of asthma, enprofylline lacks several well known clinical eVects of theophylline such as diuretic activity, CNS arousal eVects, free fatty acid releasing eVects, and gastric secretory eVects.
2
This distinct human pharmacology is evidence for the clinically eVective adenosine antagonism of theophylline and indicates that enprofylline tonically suppresses volume and acidity of gastric secretion, natriuresis, free fatty acid release, etc.
2 One might therefore conclude that adenosine antagonism should probably be avoided in asthma therapy because it may be associated with less desirable excitatory extrapulmonary eVects.
Antagonism of A 2b adenosine receptors by enprofylllne may explain the "adenosine hypothesis".
1 By inferring this, Polosa and Holgate lend greater weight to in vitro observations that disagree with the anti-asthma potency ratio between enprofylline and theophylline that may require 300 µM drug concentrations for eVective function (inhibition of mast cell release) than, for instance, to the work by Clarke et al 3 which showed that theophylline, but not enprofylline, protects against adenosine induced obstruction in asthma (see also references 18 and 21 in the review by Polosa and Holgate 1 ). If the clinical eYcacy of the xanthines in asthma cannot be explained by adenosine antagonism, phosphodiesterase inhibition may oVer an alternative explanation but, unfortunately, there are also doubts about this 4 -hence the widely promoted nonxanthine phosphodiesterase IV inhibitors cannot rely on theophylline for any predictable clinical eYcacy. Perhaps both adenosine antagonism and phosphodiesterase inhibition are examples of how theoretically attractive mechanisms may prevent unbiased exploration of truly important in vivo modes of action of anti-asthma drugs. 4 Incidentally, enprofylline was discovered by unexpected observations in complex biosystems. 4 Such exploratory in vivo work, if allowed, will continue to be a source of novel drugs; when successful, one should not be surprised to learn that the discovered class of drug was not predicted by reductionist research paradigms. The new eYcaceous compounds may thus unravel novel mechanisms-for example, omeprazole and the acid pump-or, as with the experimental drug enprofylline, the new properties will seriously question the therapeutic relevance of a widely held mechanism. AUTHORS' REPLY We read with interest the letter from Professor Persson but we remain somewhat confused about the point or points he raises. The review we wrote was intended to draw attention to adenosine bronchial provocation as a potential new marker of airway inflammation in asthma, which may be useful both clinically and to assess the action of anti-inflammatory drugs such as topical corticosteroids. 1 Because it was originally thought that enprofylline was free of A 2 receptor antagonist properties it was argued that adverse eVects of xanthines operating through this receptor could be avoided.
CARL PERSSON
2 It was also stated that, because enprofylline did have pharmacological and therapeutic actions in asthma, it was unlikely that adenosine antagonism could be involved. As pointed out in our review, it is now known that there exist two types of adenosine A 2 receptor designated A 2a and A 2b .
3 4 While enprofylline has little or no eVect against A 2a receptors, it is a selective, albeit weak, antagonist at the A 2b receptorthe adenosine receptor subtype found both on canine 5 and human 6 7 mast cells. Thus, if adenosine is released in pharmacologically active concentrations in asthmatic airways, for which there is good evidence, then enhancement of mast cell mediator release via A 2b receptors is a probable scenario. As a consequence, enprofylline could have produced at least some of its therapeutic eVect in asthma by inhibiting A 2b receptor mediated mast cell releasability. This may or may not have had implications for the clinical eYcacy of enprofylline, which is only a weak A 2b antagonist, but the A 2b receptor does present a potential new therapeutic target for asthma against which new drugs might be developed. Reasonably digestible reviews of recent clinical trials in the management of lung cancer are rare and, in general terms, this 11 chapter book is welcome. The emphasis here is on the use of chemotherapy and radiotherapy in the management of lung cancer, with eight of the 11 chapters considering these aspects, and the other three are concerned with chemoprevention, palliative medicine, and molecular biology. Nine of the 11 authors are from the USA. The chapters take the form of a traditional review and are reasonably well set out with an average of about 50 references for each topic. The strengths of the book are the comprehensive assessment of novel drug therapies, with separate chapters for paclitaxel/carboplatin, gemcitabine, and docetaxel in non-small cell lung cancer, and a separate chapter on novel drugs for small cell lung cancer, including the topoisomerase-1 inhibitors, carboplatin, and the taxanes.
Sadly, the volume lacks an adequate introduction by the Editor, which would have been useful if it had been able to point out the "major messages" from each of the chapters-for example, bringing out the importance of the recent meta-analysis of trials of prophylactic cranial irradiation in responding small cell lung cancer, or the superiority of standard intravenous regimens over low dose oral etoposide in this disease. Surgery gets no mention at all, and nor does endobronchial therapy. This is a pity since there have been major advances in our understanding of the role of endobronchial treatments, and the literature, particularly that relating to brachytherapy, is badly in need of review. Likewise, I found the chapter on palliative medicine disappointing with no consideration of psychosocial problems or some important major physical symptoms such as cough and pleural disease, and a misplaced discussion here of the meta-analysis of chemotherapy in non-small cell lung cancer. The best chapter, in my view, was that by Wagner on radiation therapy in small cell lung cancer which was a well set out discussion of the attempts that have been made to optimise local control by altering the timing and fractionation of thoracic radiotherapy, together with an up to date discussion on prophylactic cranial irradiation. The book is just about up to date enough to include the results of the important MRC study on continuous hyperfractionated accelerated radiotherapy for non-small cell disease (CHART), which must now be considered as one of the few studies on radiotherapy recently to have shown an improvement in survival compared with local control.
This book will not appeal to the nonspecialist, though it would be a useful starting point for doctors or groups who want an up to date background account as a preliminary to designing their own studies or choosing a pattern of management for their patients. Inevitably, in a fast moving field such as the assessment of novel drug therapies for lung cancer, a book like this will rapidly become out of date and, as with guidelines, I would estimate that "an update of this update" will probably be needed within a couple of years.-MFM Tuberculosis. W N Rom, S M Garay, eds. (Pp 982). Boston: Little, Brown and Company, 1995.
When asked to review this book last year I devised my own "sightation index" to assess its worth to me as a respiratory physician with the responsibility for a tuberculosis service. First a sit down to get acquainted with each other. It is big, attractive, well laid out and easy to grasp, but somewhat let down by the index. The first sections on history and epidemiology are as interesting as a British Medical Journal Christmas issue, but potentially more expensive to read in the bath-I enjoyed them. The 28 colour photos are cheerful and useful,except three brown-on-brown immunoperoxidase stains which make the eyelids droop, presumably the reason why photograph 23 of the eye is presented upside down.
During the year it sat on my shelf four colleagues borrowed the book and said it was very useful. My personal "sightation index" was 10, nearly equalling my most popular text book. I scored the usefulness of each sightation on a scale from O (no value) to 3 (excellent). I searched for M szulgai (useful about soft tissue infection and antibiotic sensitivity but little regarding lung infection, score 2/3), how to give BCG in the thigh (nothing, 0/3); management of multi-drug resistant tuberculosis (excellent, 3/3), renal tuberculosis (excellent review and helpful discussion of the role of nephrectomy and oral steroids, 3/3); M bovis (good review and references, 3/3); management of BCG complications (subcutaneous abscess not mentioned, vague advice on therapy, 0/3), medical and surgical management of tuberculosis empyema (most useful, 3/3); TB in prisons-sorry, correctional institutions or "tax supported exposure chambers for tuberculosis" (useful but review limited to problem in USA, some unrealistic recommendations, 2/3); advice on standard drug therapy (useful summary of ATS recommendations but not of drug dosages, 2/3); and directly observed therapy (again no summary of intermittent dosages, 2/3).
So the borrow index was 4, my "sightation index" was 10, and usefulness score 66%. That's pretty good (BCG apart), and I am very pleased to have it available. So should you, if you have an interest in or responsibility for a tuberculosis service.-JTM
NOTICE

New Drugs for Asthma
A two-day conference on "New Drugs for Asthma" will be held at the National Heart and Lung Institute, Imperial 
